Literature DB >> 6273179

Use of labetalol in hypertensive patients during discontinuation of clonidine therapy.

T Rosenthal, B Rabinowitz, H Boichis, E Elazar, A Brauner, H N Neufeld.   

Abstract

Eleven hypertensive patients in whom clonidine therapy had to be discontinued, were treated prophylactically with labetalol, in order to avoid a possible hypertensive crisis. Most of the known side effects, which are consistent with the withdrawal phenomenon were observed, e.g. tremor, insomnia and apprehension, but headaches and flushing did not occur. Blood pressure levels remained unchanged, despite up to a 20-fold increase in plasma catecholamines. The lack of change in serial measurements of plasma cyclic AMP level appears to indicate that adequate adrenergic blockade was induced by labetalol. Since labetalol is a potent anti-hypertensive drug, and is also effective in avoiding a possible hypertensive crisis due to withdrawal of clonidine, we propose to use it as the drug of choice whenever discontinuation of clonidine therapy is indicated.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6273179     DOI: 10.1007/bf00618771

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  24 in total

Review 1.  Drug therapy: clonidine, a new antihypertensive drug.

Authors:  W A Pettinger
Journal:  N Engl J Med       Date:  1975-12-04       Impact factor: 91.245

2.  Rebound phenomenon during gradual withdrawal of clonidine.

Authors:  R Vanholder; J Carpentier; M Schurgers; D L Clement
Journal:  Br Med J       Date:  1977-04-30

3.  Effect of labetalol on plasma noradrenaline and adrenaline in hypertensive man.

Authors:  N J Christensen; J Trap-Jensen; T L Svendsen; S Rasmussen; P E Nielsen
Journal:  Eur J Clin Pharmacol       Date:  1978-12-01       Impact factor: 2.953

4.  Plasma cyclic AMP and total catecholamines during acute myocardial infarction in man.

Authors:  P B Andreasen; L Ranek; B E Statland; N Tygstrup
Journal:  Eur J Clin Invest       Date:  1974-04       Impact factor: 4.686

5.  Clonidine and propranolol paradoxical hypertension.

Authors:  S E Warren; E Ebert; A H Swerdlin; S M Steinberg; R Stone
Journal:  Arch Intern Med       Date:  1979-02

6.  Laboratory and clinical observations with a two-column plasma catecholamine assay.

Authors:  N S Jiang; S S Stoffer; G M Pikler; O Wadel; S G Sheps
Journal:  Mayo Clin Proc       Date:  1973-01       Impact factor: 7.616

Review 7.  Adenyl cyclase as an adrenergic receptor.

Authors:  G A Robison; R W Butcher; E W Sutherland
Journal:  Ann N Y Acad Sci       Date:  1967-02-10       Impact factor: 5.691

8.  Clonidine withdrawal. Mechanism and frequency of rebound hypertension.

Authors:  G G Geyskes; P Boer; E J Dorhout Mees
Journal:  Br J Clin Pharmacol       Date:  1979-01       Impact factor: 4.335

9.  Effects of clonidine withdrawal: possible mechanisms and suggestions for management.

Authors:  S N Hunyor; L Hansson; T S Harrison; S W Hoobler
Journal:  Br Med J       Date:  1973-04-28

10.  Clonidine withdrawal in hypertension. Changes in blood-pressure and plasma and urinary noradrenaline.

Authors:  J L Reid; L M Wing; H J Dargie; C A Hamilton; D S Davies; C T Dollery
Journal:  Lancet       Date:  1977-06-04       Impact factor: 79.321

View more
  6 in total

Review 1.  beta-blockers. Drug interactions of clinical significance.

Authors:  I Blaufarb; T M Pfeifer; W H Frishman
Journal:  Drug Saf       Date:  1995-12       Impact factor: 5.606

2.  Hyperadrenergic state following acute withdrawal from clonidine used at supratherapeutic doses.

Authors:  N J Sarlis; O Caticha; J L Anderson; C Kablitz; F S Shihab
Journal:  Clin Auton Res       Date:  1996-04       Impact factor: 4.435

Review 3.  The management of hypertension.

Authors:  B N Prichard; C W Owens
Journal:  Br J Clin Pharmacol       Date:  1986       Impact factor: 4.335

Review 4.  Clinical consequences of abrupt drug withdrawal.

Authors:  C F George; D Robertson
Journal:  Med Toxicol Adverse Drug Exp       Date:  1987 Sep-Oct

Review 5.  Combined alpha- and beta-receptor inhibition in the treatment of hypertension.

Authors:  B N Prichard
Journal:  Drugs       Date:  1984       Impact factor: 9.546

Review 6.  Drug therapy for resistant hypertension: simplifying the approach.

Authors:  Samuel J Mann
Journal:  J Clin Hypertens (Greenwich)       Date:  2010-11-08       Impact factor: 3.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.